Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial

Martin, Virginie; Najbar, Wojciech; Gueguen, Sylvie; Grousson, Dominique; Eun, Hyone‐Myong; Lebreux, B.; Aubert, André

doi:10.1016/s0378-1135(02)00173-6

Cited by 69 publications

(53 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22,23 In addition, rFeIFNwas shown to have therapeutic effects in vivo on canine parvoviral enteritis. [24][25][26] The recent development of an rFeIFN-and its commercial availability provided us an opportunity to evaluate the therapeutic potential of IFN on cats presented with clinical signs associated with natural infection with FeLV or FeLV/FIV. Our study demonstrates that rFeIFN-can provide important therapeutic benefits to symptomatic cats infected with FeLV and those coinfected with FeLV and FIV.…”

mentioning

confidence: 99%

Therapeutic Effects of Recombinant Feline Interferon‐co on Feline Leukemia Virus (FeLV)‐Infected and FeLV/Feline Immunodeficiency Virus (FIV)‐Coinfected Symptomatic Cats

Mari

Maynard

Sanquer

et al. 2004

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

The clinical efficacy of a recombinant feline interferon, rFeIFN-, was evaluated for the treatment of cats presented with clinical signs associated with feline leukemia virus (FeLV) infection and FeLV/feline immunodeficiency virus (FIV) coinfection in the field. In this multicentric, double-blind, placebo-controlled trial, 81 cats meeting the inclusion criteria were randomly placed into 2 groups and treated subcutaneously with rFeIFN-(1 million [M]U/kg per day) or placebo once daily for 5 consecutive days in 3 series (day 0, 14, 60). The cats were monitored for up to 1 year for clinical signs and mortality. During the initial 4-month period, interferon (IFN)-treated cats (n ϭ 39) had significantly reduced clinical scores compared with placebo (n ϭ 42), with all cats having received concomitant supportive therapies. Compared with the control, the IFN-treated group showed significantly lower rates of mortality: 39% versus 59% (1.7-fold higher risk of death for controls) at the 9-month time point and 47% versus 59% (1.4-fold higher risk of death for controls) at the 12-month time point. The IFN treatment was associated with minor but consistent improvement in abnormal hematologic parameters (red blood cell count, packed cell volume, and white blood cell count), apparently underlying the positive effects of IFN on clinical parameters. These data demonstrate that rFeIFN-initially has statistically significant therapeutic effects on clinical signs and later on survival of cats with clinical signs associated with FeLV infection and FeLV/FIV coinfection.

show abstract

mentioning

confidence: 99%

Therapeutic Effects of Recombinant Feline Interferon‐co on Feline Leukemia Virus (FeLV)‐Infected and FeLV/Feline Immunodeficiency Virus (FIV)‐Coinfected Symptomatic Cats

Mari

Maynard

Sanquer

et al. 2004

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

show abstract

“…Considering that the subtypes of rFeIFN-α, including rFeIFN-ω, were found to be highly species-specific with regard to antiviral activity in this study, the therapeutic effect of rFeIFN-ω on Canine parvovirus infection [7,13] was caused by something other than antiviral activity. …”

mentioning

confidence: 82%

“…On account of this, the type of FeIFN which is longer in length has also been called IFN-α by other authors [14,19,25]. FeIFN-ω has been reported to inhibit the growth of canine tumor cell lines [18,21], and to have therapeutic effects on canine parvovirus infection [7,13]. We previously cloned 8 subtypes of FeIFN-α from a feline epithelial cell line [14].…”

mentioning

confidence: 99%

Expression of Feline Interferon-.ALPHA. Subtypes in Esherichia coli, and Their Antiviral Activity and Animal Species Specificity

Taira

Suzuki

Takeuchi

et al. 2005

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Two kinds of FeIFN-α consisting of 166 amino acids (aa) and 171 aa were expressed in Escherichia coli, and the purified proteins were tested for antiviral activity on homologous and heterologous animal cells. Crude FeIFN induced in feline cells revealed antiviral activity on both homologous and heterologous animal cells. In contrast, both types of recombinant FeIFN-α revealed antiviral activity only on the feline cells. All of the FeIFN-α subtypes showed high activity to vesicular stomatitis virus, and the three species of feline viruses belonging to different families. KEY WORDS: animal species-specificity, expression, feline IFN-α.

show abstract

“…Зокрема, внутрішньовенне введення котя-чого рекомбінантного інтерферону омега при-зводило до позитивного терапевтичного ефекту як у плацебо-контрольованих дослідженнях з експериментальним зараженням собак пар-вовірусом типу 2, так і в польових досліджен-нях [48,76]. Подальші багатоцентрові подвійні сліпі плацебо-контрольовані дослідження тіль-ки підтвердили ефективність котячого реком-бінантного інтерферону омега при лікуванні парвовірусної інфекції у собак [67,71]. Висока ефективність терапевтичної дії котячого реком-бінантного інтерферону омега була показана при лікуванні атопічних дерматитів у собак у клінічних дослідженнях різного дизайну: по-двійному сліпому плацебо-контрольованому дослідженні [11] та відкритому рандомізова-ному порівняльному дослідженні [121].…”

Section: The Information About the Use Of Interferons In Veterinary Munclassified

Interferons: application in veterinary medicine

Oksamytnyi¹

2017

Bìol. Tvarin

View full text Add to dashboard Cite

show abstract

Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial

Cited by 69 publications

References 19 publications

Therapeutic Effects of Recombinant Feline Interferon‐co on Feline Leukemia Virus (FeLV)‐Infected and FeLV/Feline Immunodeficiency Virus (FIV)‐Coinfected Symptomatic Cats

Therapeutic Effects of Recombinant Feline Interferon‐co on Feline Leukemia Virus (FeLV)‐Infected and FeLV/Feline Immunodeficiency Virus (FIV)‐Coinfected Symptomatic Cats

Expression of Feline Interferon-.ALPHA. Subtypes in Esherichia coli, and Their Antiviral Activity and Animal Species Specificity

Interferons: application in veterinary medicine

Contact Info

Product

Resources

About